Back to People

Nikhil Ananth

Senior Associate

About

Nikhil is a Senior Associate at F-Prime Capital and works across the healthcare sub-sectors including therapeutics, medical technology, and healthcare IT & services. Prior to joining F-Prime, Nikhil was an Associate at Audax Group in Boston, where he focused on private equity investments in healthcare and software.

Nikhil is a graduate of the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where he received a B.A. in Biology and a B.S. in Economics from the Wharton School.

  • Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India*) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bio-reactor capacities ranging from 20 litres to 2000 litres.

    Learn more at enzene.com.

  • Eywa is a global generic pharmaceutical company engaged in research and development, manufacture, marketing, sale, and distribution of generic finished dosage formulations. Learn more at www.eywapharma.com.

  • Immuneel is a pioneering clinical stage start-up company leading the change in cell & gene therapies & personalized immunotherapy for patients in India. Headquartered in Bengaluru, Karnataka, India, Immuneel is a research-led, fully integrated cell & gene therapies company committed to bringing breakthrough cancer treatments to India, affordably & build a portfolio of next generation cell therapies. Learn more at www.immuneel.com.

     

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Bangaluru, India

    • Year Invested

      2019

    • Team

      Ketan Patel, M.D.

  • Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. In July 2024, Invetx was acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business. Learn more at www.invetx.com.

  • Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Ivenix was acquired by Fresenius Kabi in 2022.

  • OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.  Learn more at www.oziva.in.

  • Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.